# Thrombolytic Therapy for Massive Pulmonary Embolism in an Antiphospholipid Syndrome Patient With Severe Thrombocytopenia: A Case Report

## TL;DR

A 34-year-old woman with a severe blood clot and low platelet count successfully received clot-dissolving treatment, challenging standard guidelines.

## Contribution

Demonstrates thrombolytic therapy can be safely used in thrombocytopenic patients with massive pulmonary embolism under specific conditions.

## Key findings

- Systemic thrombolysis was successfully administered without significant bleeding in a patient with severe thrombocytopenia.
- The patient was diagnosed with antiphospholipid syndrome following treatment.
- The case suggests thrombolytic therapy may be viable in thrombocytopenic patients under specific clinical circumstances.

## Abstract

Thrombocytopenia (TCP) is a well‐known contraindication for thrombolytic therapy due to the associated risk of bleeding. This report discusses a 34‐year‐old woman presented with massive pulmonary embolism (PE) and severe TCP. She was treated with systemic thrombolysis (ST), and fortunately, a good therapeutic response was achieved without significant bleeding. Further evaluations confirmed the diagnosis of antiphospholipid syndrome for the patient. This case highlights that ST can be a viable therapeutic option for managing massive PE in thrombocytopenic patients under specific circumstances, warranting further research into its safety and efficacy.